AKT2 and cancer: By employing this dendrimer-mediated siRNA delivery approach, the researchers achieved significant suppression of the MYC and AKT2 oncogenes, leading to a strong antiproliferative effect in various human cancer cell lines (including colorectal cancer Panc-1 cells, liver cancer HepG2 and Hep3B cells, and colorectal cancer HT-29 cells) and patient-derived cancer organoids.